Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5208MR)

This product GTTS-WQ5208MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6290MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ4408MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ4075MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ5543MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ2329MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ1402MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ4956MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ13798MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW